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ABSTRACT 
Interleukin-34 (IL-34) was recently characterized as the M-CSF “twin” cytokine, regulating the 
proliferation/differentiation/survival of myeloid cells.  The implication of M-CSF in oncology 
was initially suspected by the reduced metastatic dissemination in knock-out mice, due to 
angiogenesis impairment. Based on this observation, our work studied the involvement of IL-
34 in the pathogenesis of osteosarcoma. The in vivo effects of IL-34 were assessed on tissue 
vasculature and macrophage infiltration in a murine preclinical model based on a paratibial 
inoculation of human osteosarcoma cells overexpressing or not IL-34 or M-CSF. In vitro 
investigations using endothelial cell precursors and mature HUVEC cells were performed to 
analyse the involvement of IL-34 in angiogenesis and myeloid cell adhesion. The data revealed 
that IL-34 overexpression was associated with the progression of osteosarcoma (tumour 
growth, lung metastases) and an increase of neo-angiogenesis. In vitro analyses demonstrated 
that IL-34 stimulated endothelial cell proliferation and vascular cord formation. Pre-treatment 
of endothelial cells by chondroitinases/heparinases reduced the formation of vascular tubes and 
abolished the associated cell signalling. In addition, IL-34 increased the in vivo recruitment of 
M2 Tumour Associated Macrophages into the tumour tissue. IL-34 increased monocyte/CD34+ 
cell adhesion to activated HUVEC monolayers under physiological shear stress conditions. 
This work demonstrates that IL-34 is expressed by osteosarcoma cells, is regulated by TNF-α, 
IL-1β and contributes to osteosarcoma growth by increasing the neo-angiogenesis and the 
recruitment of M2 macrophages. By promoting new vessel formation and extravasation of 
immune cells, IL-34 may play a key role in tumour development and inflammatory diseases. 
 
Key words:  Interleukin-34, M-CSF, Endothelial cells, Angiogenesis, Cell adhesion, Tumour 
Associated Macrophages, Osteosarcoma 
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INTRODUCTION 
 
Angiogenesis and vasculogenesis are central events during embryogenesis and growth [1, 2]. 
They are also strongly implicated in the pathogenesis of inflammation, by promoting immune 
cell extravasation, and of cancer, by facilitating tumour initiation and development [3]. 
Numerous publications underscore the possible contribution in the biological mechanisms of 
the Macrophage-Colony Stimulating Factor (M-CSF), a cytokine required for the survival and 
differentiation of mononuclear phagocytic cell lines derived from monocytes such as 
macrophages and dendritic cells [4,5]. Monocytes migrate to the tumour foci attracted by the 
chemokines / cytokines produced by tumour cells. Once activated, macrophages are the main 
source of growth factors and cytokines [6]. Thus, Curry et al. reported that M-CSF induced the 
expression of VEGF from human monocytes and consequently stimulates the angiogenic 
process [7]. The tumour-associated macrophages (TAMs) significantly contribute to tumour 
growth and metastasis and are associated with poor prognosis in various forms of cancer. 
Indeed, they exert tropic roles and promote growth, angiogenesis and tumour cell motility [6, 
8]. Based on these data, the infiltrate of mononuclear phagocytes, M-CSF, VEGF and 
angiogenesis are correlated with poor prognosis in various solid cancers [9, 12]. 
 
In 2008, a new cytokine named interleukin-34 (IL-34) was discovered by Lin et al. 
based on its ability to form colony-forming unit–macrophages in human bone marrow cultures, 
with the same efficiency as M-CSF [13]. They demonstrated the binding of IL-34 to the M-CSF 
receptor (CSF-1 receptor or c-fms) expressed on human mononuclear phagocytes. More 
recently, Wang et al. reported that IL-34 was a specific driver of myeloid cell differentiation in 
the skin epidermis and central nervous system [14]. IL-34 also directs the differentiation of 
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monocytes into immunosuppressive M2 similar to M-CSF [15]. In addition, we demonstrated 
the role of IL-34 in promoting osteoclastogenesis in which this cytokine can be a substitute for 
M-CSF [16]. IL-34, like M-CSF, upregulates the chemokines produced by whole blood, 
identifying both cytokines as key partners in inflammation [17]. The role of IL-34 was 
confirmed in rheumatoid arthritis where the cytokine levels were significantly higher in the 
synovial fluids of RA patients compared with osteoarthritis patients and were correlated with 
inflammation intensity measured by the leucocyte number [18]. IL-34 shares common features 
with M-CSF, partly explaining their functional overlaps, and can be considered with M-CSF as 
“twin” cytokines that are functionally related [19]. 
 
Based on the role of IL-34 in the differentiation of mononuclear phagocytes and in 
inflammation, the present manuscript aimed to analyse the potential involvement of IL-34 in 
pathogenesis of osteosarcoma. This work focused on the role of IL-34 in the neo-angiogenesis 
and macrophage recruitment associated with tumour development. 
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MATERIALS AND METHODS 
Reagents 
Recombinant Interleukin-34 (IL-34), Macrophage-Colony Stimulating Factor (M-CSF), Tumor 
Necrosis Factor-α (TNF-α), IL-1β and basic fibroblast growth factor (FGF-2) were obtained 
from R&D Systems (Abingdon, UK). Growth factor-reduced Matrigel® was from Becton 
Dickinson (Le Pont de Claix, France). Wortmannin (PI3K inhibitor) was purchased form 
Calbiochem (France), PF573228 (FAK inhibitor) from Santa Cruz (France), PP2 (Src kinase 
inhibitor) from Abcam (France) and U0126 (ERK1/2 inhibitor) from Promega (France). Cell 
culture products and other biochemical reagents were purchased from Sigma-Aldrich (Saint 
Quentin Fallavier, France) unless otherwise specified.  
 
Tissue specimens 
Patient tumour biopsy specimens were collected at Nantes University Hospital (Nantes, France) 
(Supplementary Data 1). Samples were obtained following patient informed consent, and after 
ethical approval by the Nantes University Hospital Ethics Committee.  
 
Cell characterization, culture and treatment 
Umbilical cord blood samples were collected from consenting mothers (n=20). The study was 
approved by the ethics committee of the Hôpital des Instructions et des Armées de Begin 
(France) (ref. 201008043234797), and the protocol conformed to the Declaration of Helsinki. 
Endothelial cells from human umbilical cords (HUVECs) and endothelial colony-forming cells 
(ECFCs) from human umbilical cord blood were isolated, expanded and characterized as 
previously described [20]. The presence of Weibel-Palade bodies, combined expression of 
endothelial markers (CD31, KDR, Tie-2, CD144), and dual positivity for DiI-AcLDL uptake 
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and BS-1 lectin binding confirmed the endothelial phenotype of the ECFCs thus obtained. 
ECFCs do not express leukomonocytic markers such as CD45 and CD14 [121. One day before 
the experiments, the cells were growth-arrested for 18 h in EBM2, 2 % FCS (starvation 
medium) and released from growth arrest by adding EBM2, 5 % FCS (basal medium), with or 
without 50 ng/mL of IL-34 or 100 ng/mL M-CSF in the presence or absence of FGF-2 (5 
ng/mL) at 37°C. Cells were then washed, detached with PBS-EDTA or trypsinized at 37°C, 
and washed twice with PBS before use. All assays were performed at least in triplicate, with 
cells cultured for less than 30 days. In some cases, ECFCs were pretreated for 2 h at 37°C with 
a cocktail of heparinase I, II and III (0.5 U/mL) and 0.2 U/ml chondroitinases A, B and C, for 1 
hour at 37°C, then extensively washed with PBS before IL-34 stimulation.  
 
In vitro angiogenesis assays 
To investigate the effects of IL-34 and M-CSF on ECFC adhesion, proliferation and tubular 
morphogenesis, ECFCs were stimulated as described above. Cell outgrowth, adhesion and in 
vitro tube formation were evaluated as previously described [20]. To assess, the effects of 
pharmacology inhibitors on the tubular network formation, ECFCs were pre-treated with 
inhibitors of FAK (PF 573228), Src (PP2) PI3K.Akt pathway (Wortmannin) and ERK-1/2 
(U0126). Each inhibitor was added to ECFC 30 minutes prior to each treatment according to 
manufacturers’ instructions and maintained all along the time of culture and before to add 50 
ng/mL of IL-34. Pharmacological inhibitors were dissolved in dimethyl sulfoxide (DMSO) and 
the final concentration of DMSO in samples was less than 0.2 % (1/1000). In preliminary 
experiments, no significant influence of solvents on cell proliferation and morphology was 
observed. No toxic effect of inhibitors was observed on endothelial precursors.  
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Monocytes and CD34
+
 cell isolation from human peripheral blood 
Mononuclear cells were isolated by density-gradient centrifugation from fresh peripheral blood 
mononuclear cells collected from healthy donors provided by the French blood bank institute 
(EFS) under an agreement with Paris Descartes University (C CPSL UNT n°12/EFS/064). 
Monocytes were isolated with the Monocyte Isolation Kit II (MACS Miltenyi Biotec, Paris, 
France) by negative selection. 
 
Shear-flow adhesion assays 
Flow adhesion experiments were conducted with a parallel-plate chamber in physiological 
shear stress conditions as previously described [22, 23]. Briefly, calcein-labelled freshly 
isolated monocytes/CD34+cells (3x106) were perfused on activated HUVEC monolayers for 15 
min at 37°C at a shear rate of 50 s-1. Cell adhesion was dependent on endothelial activation and 
on the shear rate, as it was optimal at shear rates below 350 s-1, whereas far fewer cells adhered 
at 500 s-1. Adherent cells were visualized by phase-contrast microscopy. All experiments were 
observed in real-time and videotaped for offline analysis. Fluorescence micrographs of 40 
random microscopic fields (obj. x10, 1 cm2) were collected with Replay software (Microvision 
Instruments, France). Data were expressed as the number of adherent cells per field. The 
results of 4 different experiments were pooled for each study. The pattern of adhesion at 50 
sec-1 was also analyzed to determine the number of tethering cells and adherent cells 
(immediate full arrest). Adherent monocytes were tested for resistance to detachment from the 
modelled endothelium by increasing the flow rate from 50 to 5000 s-1 over 1 minute, and by 
counting the number of remaining adherent cells at one-minute intervals. 
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Murine Matrigel
®
 plug assay 
Animal care conformed to French guidelines (Services Vétérinaires de la Santé et de la 
Production Animale, Ministère de l’Agriculture, Paris France) and experiments were in 
agreement with the guidelines of the University Paris-Descartes Institutional Animal Care and 
Use Committee (C75.06.02). Ice-cold Matrigel® (BD, 8 mg/ml) was mixed with phosphate-
buffered saline (PBS) plus FGF2 (350 ng/ml) alone or supplemented with 500 ng/ml of IL34 or 
M-CSF, then injected subcutaneously into male C57BL/6J mice (8 weeks old, from Elevages 
Janvier, France). The Matrigel® plugs were recovered 14 days later. Haemoglobin content was 
measured with Drabkin’s reagent (Sigma). Functional vessels were identified by light 
microscopy as vessels containing red blood cells. 
 
Western Blot Analysis 
ECFCs or HUVECs treated with 200 ng/mL of IL-34 or M-CSF for 1 to 15 min. The proteins 
obtained form the cell lysates were separated by SDS-PAGE and transferred to immobilon-P 
for Western blot.  The membranes were blotted with the antibodies (1/1000) anti-pFAK 
(Tyr925), anti-pAkt (Ser473), anti-pSrc (Tyr416), anti-p38 (Thr180/Tyr182), anti-pERK 1/2 
(Thr202/Tyr204), or with antibodies against the total forms of protein above (Cell Signalling, 
Danvers, MA, USA). The membrane was probed with the secondary antibody (1/10000) 
coupled to horseradish peroxidase. Antibody binding was then visualized with an ECL kit 
(Pierce Protein Biology Products, Thermo Scientific Rockford, USA). The luminescence 
detected with a Charge Couple Device (CCD) camera was quantified using the GeneTools 
programme (Syngene, Cambridge, United Kingdom). 
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Lentivirus production and osteosarcoma cell transduction  
Vector pEZ-Lv105 (GeneCopoeia, Rockville, USA) containing either the human IL-34 gene 
(Accession Number BC029804) or the human M-CSF gene (Accession number NM_000757) 
were used to produce lentiviral particles. The pEZ-Lv105-eGFP (GeneCopoeia) was used as a 
control. Lentivirus were produced using packaging vectors as described by Dull et al.24 Briefly, 
6 x106 HEK293FT cells (human embryonic kidney cells optimized for viral production) were 
seeded and transfected 24 h later with 3 µg of each packaging plasmid (pLP-1, pLP-2 and pLP-
VSV-G) and 9 µg of the transgene of interest (pEZ-Lv105-eGFP, pEZ-Lv105-M-CSF or pEZ-
Lv105-IL-34); virus-containing supernatants were collected 48 h post-transfection and 
concentrated 60-fold by ultrafiltration. For titration, serial dilutions of virus containing 
supernatants were tested on HEK293FT cells that were analyzed for EGFP expression 4 days 
post-infection by flow cytometry (FACSCalibur Flow cytometer, BD Biosciences, Le Pont de 
Claix, France). The titres obtained were between 10x106 and 10x107 viral particles/µL. Human 
osteosarcoma KHOS/NP (HOS), U2OS, Saos2 and MG63 cells purchased from the ATCC 
(USA) were cultured in DMEM (Lonza, Belgium) supplemented with 5% of Foetal Bovine 
Serum (FBS; Hyclone Perbio, France). To generate stably modified HOS cell lines, 2x104 HOS 
cells were seeded in a 24-well plate in 300 µl medium and infected with a multiplicity of 
infection of 10 particles/cell. After transduction, the cells expressing the transgene were 
selected at confluence with 2µg/mL puromycin (Sigma, France) to obtain a stable population. 
The eGFP, M-CSF and IL-34 expression levels were controlled by flow cytometry analysis for 
eGFP and IL-34 (R&D), ELISA for M-CSF (R&D) and also RT-qPCR (Supplementary Data 
1A,B). 
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RNA isolation and real-time PCR 
Total RNA was extracted using NucleoSpin®RNAII (Macherey Nagel, Duren, Germany) with 
one stage of DNase I treatment (25 units, 15 min) to prevent genomic contamination. 1 µg of 
total RNA was used for first strand cDNA synthesis using the ThermoScript RT-PCR System 
(Invitrogen). Real-time PCR was performed on 20 ng of reverse transcribed total RNA 
(cDNA), 300 nM of primers and 2x SYBR Green Supermix (Biorad, Marnes-la-Coquette, 
France). Quantitative PCRs (qPCR) were carried out on a Bio-Rad CFXTM System (Biorad). 
Analyses were performed using human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
orhuman hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1) as invariant controls. 
The sense and antisense primers used are as follow: human HPRT1 (forward: 
TGACCTTGATTTATTTATTTTGCATACC, reverse: CGAGCAAGACGTTCAGTCCT); 
human GAPDH (forward: TGGGTGTGAACCATGAGAAGTATG, reverse : 
GGTGCAGGAGGCATTGCT) ; human IL-34 (forward: AATCCGTGTTGTCCCTCTTG, 
reverse: CAGCAGGAGCAGTACAGCAG); human M-CSF (forward: 
GTTTGTAGACCAGGAACAGTTGAA, reverse CGCATGGTGTCCTCCATTAT). 
 
Confocal microscopy  
Osteosarcoma cells were cultured in a plastic chamber on microscope glass slides (Millicell EZ 
Slide, Millipore, Billerica, MA, USA) were stimulated or not with 10 ng/mL of TNF-α or IL-
1β for 24 h. The cells were then washed in PBS, fixed in 4% paraformaldehyde for 10 min at 
room temperature, permeabilized with triton X-100 0.1% for 20 min and incubated with a 
blocking solution [BSA 1% with 1% of non-immune goat serum (Dako, Les Ulis, France) and 
0.05% triton] for 30 min at room temperature. The cells were incubated with either the primary 
antibody against IL-34 (Diaclone, INSERM UMR 957) or the blocking solution as the negative 
control for 90 min at 37°C. After washings, Alexa Fluor 488 secondary antibody (1/200) was 
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added for 90 min at room temperature. Actin filaments were stained using 546-conjugated 
phalloidin (1/300) and nuclei stained with DAPI (1/5000).  
 
Osteosarcoma mouse model 
The mice (Elevages Janvier, Le Genest Saint Isle, France) were housed in pathogen-free 
conditions at the Experimental Therapy Unit (Faculty of Medicine, Nantes) in accordance with 
the institutional guidelines of the French Ethical Committee (CEEA PdL 06 ethical committee, 
authorization number: 1280.01) and under the supervision of the authorized investigators. Five-
week-old female Rj:NMRI-nude mice (n=8 per group) were anaesthetized by inhalation of an 
isoflurane/air mixture (2%, 1L/min) before i.m. inoculation of 1.5x106 human HOS 
osteosarcoma cells over-expressing M-CSF, IL-34 or transduced by the empty vector. 
Osteosarcoma cells were injected in close proximity to the tibia, rapidly leading to tumour 
growth in the soft tissue with secondary contiguous bone invasion [25]. Tumours appeared at 
the injection site 8 days later and their volumes were calculated for 27 days by measuring two 
perpendicular diameters using calipers, according to the following formula: V = 0.5 x L x (S)2, 
in which L and S are, respectively, the largest and the smallest perpendicular diameters as 
previously described [25]. To determine the effect of IL-34 in the formation of lung metastases, 
mice were sacrificed by cervical dislocation at an equivalent volume of 1500 mm3. Lung 
metastases were macroscopically and manually scored in each animal. The overexpression of 
M-CSF or IL-34 in explanted tumour tissues established from inoculation of M-CSF- or IL-34-
transduced HOS osteosarcoma cells was validated by RT-qPCR (Supplementary Data 1C). 
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Immunohistochemistry 
After euthanasia, tumour samples were preserved and fixed in 10% of PFA, decalcified with 
4.13% of EDTA, and 0.2% of PFA in PBS using a microwave tissue processor (KOS, Mikron 
Instruments, USA) for 4 days and embedded in paraffin. Three micrometer sections were then 
stained for mouse CD146 (Abcam, 1/200), mouse CD31 (Abcam, 1/100) [25], mouse ionized 
calcium-binding adapter molecule 1 (IBA-1, Abcam, 1/700) or mouse arginase-1, (BD 
Biosciences, 1/500). IL-34 was detected as previously described by Chemel et al [18]. Images 
were automatically numerized (nanozoomer, Hamamatsu photonics) before quantification. The 
negative control was analysed using a similar procedure, excluding the primary antibody and 
using a normal rabbit-irrelevant IgG at 1/100 (R&D Systems). The image analysis was 
performed on the whole tumour sections with FIJI (ImageJ), the region of interest (R.O.I.) 
excluding necrotic tissue and the skeletal muscle. The percentage of CD146, IBA-1 or Arg-1 
positive cell surfaces was quantified after a DAB colour deconvolution function, using the pixel 
density of the red staining, and reported to the R.O.I. selected.  
 
Statistical analysis 
Differences between in vitro experimental conditions were assessed with Student’s t test or 
one-way ANOVA followed by the Mann–Whitney test. In vivo results were analyzed using a 
non-parametric one-way analysis of variance followed by a Dunn’s post-hoc test using 
GraphPad InStat v3.02 software. The results are given as a mean ± SEM of at least three 
independent experiments. Results were considered significant at p values ≤ 0.05. 
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RESULTS 
IL-34 is expressed by osteosarcoma cells, promotes osteosarcoma progression and 
increases the establishment of lung metastases 
The expression of IL-34 was first analysed by qPCR in 12 biopsies of human osteosarcomas 
(Supplementary Data 2A). The results clearly demonstrated that all osteosarcoma tissues 
expressed IL-34 (Supplementary Data 2B) with apparent heterogeneous expression levels. In 
addition, our data were validated in a cohort of 27 osteosarcoma biopsies described by Dr 
Yamada from the National Cancer Center of Tokyo [26] (GEO Series GSE14827) in which all 
osteosarcoma samples expressed IL-34 (Supplementary Data 2C, D). The expression of IL-34 
was next assessed in 4 human osteosarcoma cell lines (HOS, U2OS, SaoS2, MG63) and was 
demonstrated in all cell lines studied (Supplementary Data 2B). We next assessed the 
expression of IL-34 by various osteosarcoma cells in vitro and its regulation by TNF-α and IL-
1β. IL-34 messenger RNA was detectable in non-stimulated cells. Stimulation with TNF-α and 
IL-1β resulted in a significant dose-dependent induction of IL-34 mRNA (Supplementary Data 
3A). Confocal microscopy analyses confirmed that TNF-α and IL-1β upregulated the 
expression of IL-34 by osteosarcoma cells at the protein level compared to untreated cells 
(Supplementary Data 3B).  IL-34 expression was then analyzed by immunohistochemistry in 
human osteosarcoma biopsies. In all samples studied, most of osteosarcoma cells exhibited a 
positive nuclear and/or cytoplasmic immunostaining for IL-34  (Supplementary data 4A-D). As 
previously observed for giant cell tumours of bone, multinucleated cells also expressed IL-34 
staining (Supplementary Data 4A) [16] in contrast to osteocytes which were negative 
(Supplementary Data 4B).  
To determine the potential involvement of IL-34 in the pathogenesis of osteosarcoma, 
human HOS osteosarcoma cell line expressing a very low level of IL-34 (Supplementary Data 
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2B), was genetically modified to overexpress the corresponding cytokine. The volume of the 
tumours induced in Nude mice by the different cell line generated was then compared (Figure 
1A). IL-34 overexpression increased significantly the tumour progression compared to the 
control groups (non transduced cells and HOS cells transduced with an empty vector) (p < 
0.001). Indeed, the mean tumour size of established tumours from IL-34-overexpressing HOS 
cells (2131 +/- 392 mm3) was 57% higher compared to control group (1359 +/- 146 mm3 for 
the empty vector transduced HOS cells (Figure 1A). Similarly, the progression of the tumours 
induced by M-CSF-transduced HOS cells was significantly upmodulated compared to the 
control groups (at day 27, tumour volumes: 1805 +/- 218 mm3 for the M-CSF group, compared 
to 1201 +/- 180 mm3 for the non transduced control group, p < 0.01) (Figure 1A).  Because 
osteosarcoma cells exhibit a high ability to induce lung metastases, we compared the number of 
lung metastases formed with the different cell lines generated (Figure 1B). Interestingly, at an 
equivalent volume of primary tumours (1500 mm3), the number of lung metastases formed in 
groups overexpressing IL-34 and M-CSF were significantly higher than in the control groups (p 
< 0.05 and p < 0.001 respectively) (Figure 1B). Overall, these data reveal that IL-34 and M-
CSF promote osteosarcoma development and facilitate the lung metastatic process.  
 
IL-34 upmodulates the formation of neo-vessels in HOS mouse osteosarcoma  
To examine the mechanisms underlying the effect of IL-34 and M-CSF on tumour progression, 
histopathological investigations were carried out on the tumour tissues.  At the endpoint of the 
experiment (tumour size: 1500 mm3), CD146+ vessels into the tumour mass were assessed by 
immunohistochemistry (Figure 1C). The density of neo-vessels was significantly increased in 
tumours over-expressing IL-34 compared to the control group (Figure 1C, p<0.05). CD31 
showed similar patterns of expression strengthening the pro-angiogenic effect of IL-34 
(Supplementary Data 5). M-CSF over-expressing HOS cells exhibited a slight but not 
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significant increase in the CD146+ and CD31+ vessels (Figure 1C, Supplementary Data 5). To 
confirm the pro-angiogenic effect of IL-34 in vivo, we used an in vivo Matrigel® plug assay, a 
non tumour model. As shown in Supplementary Data 6, plugs from the PBS control group and 
plugs containing M-CSF alone were mostly translucent and pale, indicating little or no vessel 
formation after two weeks. In contrast, plugs containing FGF-2 and IL-34 alone were redder, 
indicating the very early stages of a vasculature. However, plugs containing IL-34 and FGF-2 
together had a modest non-stimulatory effect on angiogenesis compared to FGF-2 alone. IL-34 
alone was able to recruit endothelial cells to form vascular structures within the Matrigel® 
plugs. In addition, plugs treated concurrently with FGF-2 and M-CSF had an intense red 
colour, indicating the presence of abundant new capillary vasculature formation. An analysis of 
haemoglobin content confirmed that FGF-2 and M-CSF together enhanced neo-angiogenesis 
compared to M-CSF alone (Supplementary Data 6). Thus, M-CSF appeared to enhance the 
FGF-2-induced recruitment of circulating cells, suggesting a synergistic effect on angiogenesis 
in vivo. These data demonstrate that IL-34 is a pro-angiogenic factor in vivo and suggest its 
implication in tumour development. 
 
IL-34 induces tubular morphogenesis of ECFCs in Matrigel
®
 and its activity depends on 
cell surface glycoaminoglycans 
We next explored in vitro the mechanistic effect of IL-34 in endothelial cells. We first focused 
our work on ECFCs because this cell type is currently proposed as the cell type at the origin of 
newly-formed vessels. Proliferation was examined by measuring cell phosphatase activity 
based on the release of pNPP measured after 48 h of incubation in basal medium (EBM2, 5% 
FCS) containing IL-34 or M-CSF. IL-34 clearly demonstrated a bell-shaped response curve 
with optimum proliferation occurring at 50 ng/mL (p<0.01) and an inhibitory activity at high 
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doses (Figure 2A) whereas M-CSF enhanced ECFC proliferation in a concentration-dependent 
manner, starting at 6 ng/mL after 48h of incubation (Figure 2B). IL-34 induces an additive 
effect to enhance cell proliferation, in the presence of FGF2 (p<0.01 versus FGF-2 alone, 
Figure 2C).    
ECFCs were incubated overnight in starvation medium (EBM2 + 2.5% FCS) then 
stimulated for 24h with IL-34 or M-CSF in basal medium (EBM2 + 5% FCS), with or without 
FGF-2 before seeding on Matrigel® for 18h. Without FGF-2 pretreatment, ECFC did not form 
any tubular structures, even in the presence of 50 ng/mL IL-34 and 100 ng/mL M-CSF, 
remaining as individual cells or small aggregates (Figure 2D). In contrast, 18h after seeding, 
pretreatment with FGF-2 promoted ECFC organization into branched structures and 
pseudotubes with enclosed areas (p<0.01) (Figure 2E). The tubular network was significantly 
more extensive in the presence of 50 ng/mL IL-34 (1.3 fold increase, p<0.001) or 100 ng/mL 
M-CSF (1.8 fold increase, p<0.001) and 5 ng/mL FGF2 compared to the FGF2 alone.  
This effect is associated with the activation of signalling pathways in ECFCs and in 
HUVECs (Figure 3, Supplementary Data 7). In ECFCs, IL-34 rapidly induced the 
phosphorylation of FAK and ERK1/2 compared to the non-treated cells, in contrast to Akt and 
Src phosphorylations that were slightly modulated (Figure 3A, Supplementary Data 7). In 
HUVECs, IL-34 increased mainly the phosphorylation of Src, FAK (Figure 3B, Supplementary 
Data 7) and p38 (Figure 3C, Supplementary Data 7). M-CSF induced differential modulations 
of signalling pathways in EFCFs compared to IL-34 as shown for P-FAK. Indeed, in ECFCs, P-
FAK was not modulated in the presence of M-CSF in contrast to IL-34 (Figure 3A, 
Supplementary Data 7). In HUVECs, M-CSF induced similar patterns of phosphorylation 
compared to IL-34 (P-FAK, P-Src and P-p38) (Figure 3). As expected, FGF-2 increased the 
phosphorylations of p38, Src, ERK1/2 and the addition of M-CSF did not modify the response 
of FGF2 (Figure 3C). P-38 and P-Src induced by FGF-2 were slightly decreased by addition of 
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IL-34 (Figure 3C).  To evaluate the functional involvement of the signaling pathways that 
could be involved in IL34 effect on tubular morphogenesis of ECFC on matrigel, cells were 
cultured in the presence of IL34 (50 ng/mL) and (5 ng/mL FGF2) and different protein kinase 
inhibitors: PI3K/Akt inhibitor Wortmannin; Src inhibitor PP2; ERK1/2 inhibitor UO126; and 
FAK inhibitor PF573228 (Figure 3D). As expected, IL-34 and FGF2 induced an additive effect 
for increasing the formation of vascular tubes. Src and ERK1/2 inhibitors (PP2 and UO126 
respectively) abolished the formation of vascular tubes compared to the control group (P < 
0.001). FAK and Akt inhibitors (PF 573228 and Wortmannin) also suppressed the cytokine 
effects (Figure 3D, p < 0.01 compared to the FGF2+IL34 group). These results support that 
these 4 protein kinases (PI3K, Src, FAK and ERK) play a key role in the effect of IL-34 on cell 
differentiation into vascular cords. 
As revealed by RT-qPCR, ECFCs and HUVECs did not express the M-CFR (data not 
shown). Consequently the IL-34 induced signalisation in endothelial cells appears M-CSFR-
independent in the culture conditions used.  Because glycosaminoglycans are strongly involved 
in the biology of endothelial cells, we investigated their involvement in IL-34-induced 
angiogenesis (Figures 3E, 3F). The pretreatment of HUVECs by a cocktail of enzymes 
composed by chondroitinases and heparinases resulted in a disorganization of branched 
structures and pseudotubes formed in Matrigel® (Figure 3E). In addition, the abrasion of 
glycosaminoglycans strongly inhibited the FAK and Src phosphorylations induced by one 
minutes of IL-34 treatment and led to the dephosphorylation of both proteins after 5 minutes of 
IL-34 treatment (Figure 3F). Overall, these data strengthen the implication of 
glycosaminoglycans in IL-34-induced angiogenesis. 
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IL-34 promotes the recruitment of M2 TAM in osteosarcoma 
Given the involvement of IL-34 in osteosarcoma tumour growth and its ability to induce, in 
vitro, the differentiation of human monocytes into immunosuppressive macrophages [15], we 
investigated by immunohistochemistry the populations of osteosarcoma-associated 
macrophages. As shown in Figure 4, HOS osteosarcoma was moderately infiltrated by 
macrophages revealed by IBA-1 staining. Interestingly, IL-34-overexpressing tumours exhibit a 
three-fold increase of the IBA-1 positive TAMs compared to the control group (Figure 4A, p < 
0.01) whereas M-CSF-overexpressing tumours showed a slight but non significant increase of 
TAM number. We then investigated the infiltration of M2 macrophages by arginase-1 
expression (Figure 4B). The number of Arginase-1 macrophages was markedly increased in the 
tumour tissue formed by IL-34- and M-CSF-transduced cells compared to the control group [a 
5- (p < 0.05) and 6- (p < 0.01) fold increase for M-CSF and IL-34 respectively compared to the 
empty vector-transduced HOS cells, Figure 4B]. These data demonstrate that IL-34 promotes 
the recruitment of M2 macrophages in osteosarcoma. 
 
IL-34 pre-conditioning promotes monocyte/CD34
+
 adhesion to activated HUVEC 
monolayers under physiological shear stress conditions 
We next investigated whether IL-34 had a direct effect on monocyte adhesion to the 
endothelium, under physiological flow conditions. Freshly isolated monocytes were stimulated 
for 30 min with 50 ng/mL in medium supplemented with 5% FCS, prior to adhesion. We used a 
flow-based adhesion assay using HUVEC monolayers to investigate the binding of cytokine-
stimulated monocytes to an activated endothelium. The experimental conditions mimicked the 
shear forces encountered by cells adhering to vascular endothelial cells in vivo. As shown in 
Figures 5A-B, incubation of monocytes with recombinant IL-34 significantly increased the 
percentage of adherent monocytes (163% versus 100% control after 10 min; p<0.05), an effect 
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similar to that observed with SDF-1 pre-treatment [22]. IL-34 pre-treatment increased the rate 
of cell tethering to the activated modelled endothelium by about 50% at a shear rate of 50sec-1 
(Figure 5C). In addition, IL-34-stimulated monocytes adhered more strongly and were more 
resistant to washing than control untreated cells, at shear rates up to 2500 s-1 (Figure 5D). A 
similar experiment was carried out on CD34+ cells and the results were compared to those of 
monocytes. Il-34 treatment of CD34+ cells resulted in a further 2-fold increase in cell adhesion 
similarly to monocytes (p<0.001, Figures 6A-B) (Supplementary Video 1, Supplementary 
Video 2). The effect on CD34+ stem cell tethering was comparable to that observed with 
monocytes (Figure 6C-D). However, the resistance to detachment of IL-34-treated CD34+ cells 
was lower than with monocytes in the same experimental conditions (Figures 6E-F) 
(Supplementary Video 3, Supplementary Video 4). 
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DISCUSSION 
Inflammation is a key biological process enabling the tissues to develop a host defense 
mechanism to injury, infectious agents, cancers or immune dysregulation. It is now recognized 
that endothelial cells play a central role in these mechanisms [27]. The inflammatory 
environment is effectively characterized by an enrichment of immune cells (neutrophils, 
eosinophils, mast cells, NK cells, macrophages, dendritic cells and lymphocytes) that promote 
angiogenesis by releasing pro-angiogenic factors and by remodelling the extracellular matrix, 
allowing blood vessel formation [28]. In return, endothelial cells from neo-vessels increase the 
inflammation by recruiting immune cells locally, facilitate their extravasation and macrophage 
polarization [29]. In addition, the hypoxia environment exacerbates this phenomenon [30]. 
The present data demonstrated that osteosarcoma cells express IL-34. Osteosarcoma 
cells originate from a mesenchymal stem cell committed toward osteoblastic differentiation 
[31].  Previous works showed that IL-34 was produced in bone marrow [32] and in osteoblasts 
[33] and that expression was increased by inflammatory cytokines such as TNF-α and IL-
1β [18, 33]. Similarly, TNF-α and IL-1β upmodulated the expression of IL-34 in osteosarcoma 
cell lines. It is admitted that an inflammatory environment is established during the tumour 
development. In this context, the IL-34 production by osteosarcoma cells (as shown in human 
biopsies) would facilitate the formation of blood vessels and the macrophage infiltration by 
modifying the tumour microenvironment. The present work shows that IL-34 exerts pro-
angiogenic function both in vitro and in vivo and for the first time that IL-34 can regulate the 
proliferation of endothelial colony-forming cells. IL-34 modulated FAK, Src, Akt and ERK1/2 
signaling pathways in endothelial cells and as expected these signal molecules appeared critical 
for appears for IL-34-mediated angiogenesis. Indeed, FAK is a key mediator of integrin 
signaling as well as important components of signaling by numerous surface receptors and 
FAK knockout mice models demonstrated its critical role critical role of FAK in angiogenesis 
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during embryonic development and cancer progression [34-35]. FAK was found to mediate Src 
phosphorylation [36] and consequently Scr modulates endothelial phenotype and angiogenesis 
[37, 38]. Similarly, Akt and ERK1/2 play critical roles in the regulation of endothelial cells and 
vascular homeostasis [39, 40]. In addition, activation of both ERK1/2 and PI3K is required for 
inducing a complete cell proliferation of endothelial cells in response to FGF2 [41]. However, 
recent data revealed that all of these inhibitors are able to targets many other kinases. Thus, 
Slack-Davies et al have shown that FAK inhibitor PF 573228 inhibited the growth of FAK-
deficient fibroblasts [42]. Similarly, Kristoffer et al have recently demonstrated that Src-
“selective” inhibitor PP2 at 10 µM is non-selective and inhibited many other kinases with 
similar affinities [43]. Finally, Liu et al showed that wortmannin at 10 µM not only inhibits 
PI3/AKT kinase but also mitosis-related polo-like kinases [44]. Consequently, in addition to 
FAK, Akt, Src, we can not exclude the contribution of other undetermined kinases in the IL-34-
mediated vascular formation.  
Our data are in agreement with those published by Emese et al. revealing a potential 
role of IL-34 in angiogenesis associated to inflammatory arthritis [45]. The indirect role of M-
CSF in angiogenesis has already been reported by its ability to recruit mononuclear phagocytes 
that increase VEGF levels [7] or by the induction of systemic VEGF from skeletal muscles 
[46]. Based on the present data, and similar to M-CSF, IL-34 exhibits direct effects on 
endothelial cells. IL-34 effectively activates the signalling pathway in endothelial cells, and 
controls their proliferation and the formation of pseudotubes in vitro and in Matrigel® plugs in 
vivo. In addition, in absence of M-CSFR, the pro-angiogenic activity of IL-34 required the 
presence of glycosaminoglycans. Heparan sulfate and chondroitin sulfate influence multiple 
cellular properties such as proliferation/differentiation, migration and angiogenesis, most often 
by regulating the biological activities of cytokine/growth factors [47-49]. While the effects 
observed are independent of the autocrine SDF-1 (data not shown), IL-34 may also modulate 
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angiogenesis by stimulating the secretion of VEGF, IP-10, MCP-1 or IL-8 (data not shown), 
data in agreement with those published by Eda et al. [17]. Recently, Nandi et al. identified the 
receptor-type protein-tyrosine phosphatase ζ (PTP-ζ) as a novel IL-34 receptor [50].  PTPζ is in 
fact predominantly expressed as a chondroitin sulfate proteoglycan and is highly abundant in 
the brain. In addition, PTP-ζ is expressed by endothelial cells and regulates endothelial cell 
migration by a strong interaction with ανβ3 [51].
 Overall, these data established a direct effect of 
IL-34 in endothelial cells through its binding to cell membrane-associated glycosaminoglycans. 
This binding may explain in part the therapeutic benefit of glycosaminoglycans in the treatment 
against synovial inflammation in arthritis [52]. 
IL-34, like M-CSF, plays a part in the inflammatory process by the control of 
macrophage survival, migration and polarization [13, 14, 16, 18]. IL-34 drives in vitro the 
polarization of macrophages towards an immunosuppressive phenotype and function [15], data 
in agreement with our present in vivo observations. Numerous reports have described the 
accumulation of TAMs in tumour mass during their development. TAM density is associated 
with poor prognosis and release of trophic factors for tumour cells and angiogenesis.  
Consequently, TAMs facilitate the metastatic process [53]. In osteosarcoma, Buddingh et al. 
demonstrated that macrophages in osteosarcoma have both M1 and M2 characteristics. In 
addition, these authors observed an interesting relationship between CD14+/CD163+ M2 
macrophage and angiogenesis [54]. Our results are in agreement with these data and strengthen 
the involvement of IL-34 in the inflammation associated with cancer development. Indeed, IL-
34 promotes the adhesion of mononuclear phagocytes (monocyte/CD34+) to activated 
endothelial cells under physiological shear stress conditions. Il-34 may maintain the cancer 
inflammatory process by facilitating the extravasation of mononuclear phagocytes and may 
orientate the polarization of these cells toward an M2 phenotype. The phenomenon would be 
completed by the pro-angiogenic effect of IL-34 related to the M2 macrophage polarization 
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and/or recruitment that increases the tumour vasculature as shown in vivo in the osteosarcoma 
model. Tumour growth and metastatic dissemination are significantly reduced in mice bearing 
an inactivation of the Macrophage-Colony Stimulating Factor (M-CSF) gene, due to 
angiogenesis impairment [55]. Similarly, DeNardo et al. provide evidence that the response to 
chemotherapeutic agents is partly controlled by the invaded mononuclear phagocytes [53]. In 
their work, chemotherapy induces mammary epithelial cells to produce pro-
monocyte/macrophage factors such as M-CSF and IL-34 that enhance TAM infiltration. 
Interestingly, an antagonist inhibitor of the M-CSF receptor abolished M-CSF and IL-34 
activities and improved the survival of animal-bearing tumours (reduced initial tumour 
development and lung metastases). 
Although IL-34 has been characterized in the literature as the M-CSF “twin” cytokine 
showing common features, the present study revealed differential biological activities on the 
formation of vascular tubes (signaling pathways, functional interactions with FGF2, etc). Our 
results identify IL-34 as a novel cytokine promoting osteosarcoma progression by increasing 
the tissue vasculature, by stimulating the recruitment of macrophages and their differentiation 
toward M2 phenotype. Consequently, IL-34 appears as a pro-metastatic regulator in 
osteosarcoma. By regulating mononuclear phagocyte adhesion to the endothelium, 
angiogenesis and macrophage recruitment, our data suggest that IL-34 may play also a major 
role in inflammatory diseases. Targeting the M-CSF/IL-34/M-CSFR triad represents promising 
therapeutic approaches in oncology and autoimmune disorders. 
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FIGURE LEGENDS 
 
Figure 1: IL-34 promotes osteosarcoma growth, increases the number of lung metastases 
and the tumour vasculature in a mouse osteosarcoma model. Human HOS osteosarcoma 
cells overexpressing IL-34 (HOS-IL34), M-CSF (HOS-MCSF), transduced by the empty vector 
(HOS) were inoculated in close proximity to the tibia of female Rj:NMRI-nude mice (n=8 per 
group). (A) Follow-up of tumour volume for 27 days. (B) All mice were sacrificed by cervical 
dislocation at an equivalent volume of 1500 mm3 and the number of macroscopic lung 
metastases were scored manually. (C) immunohistochemical assessment of CD146 was carried 
out (Left Panel), and the percentage of CD146 positive vessel area was reported to the region of 
interest (R.O.I.) determined by ImageJ software (Right panel). *p < 0.05 compared to the 
control HOS group. 
 
 
Figure 2: IL-34 and M-CSF mediates the proliferation of endothelial colony-forming cells 
(ECFCs) and the tubule formation. (A-B) IL-34 and M-CSF induce ECFC proliferation in a 
dose-dependent manner after 48h of incubation. (C) IL-34 induces additive effect in the 
presence of FGF-2 after 24h of culture. (D-E) After 24h of culture in basal medium, in the 
presence or absence of 50 ng/mL IL34 and 100 ng/mL M-CSF, ECFCs were immediately 
seeded on Matrigel® in growth factor-depleted basal medium. After 18h of culture the cells 
were fixed and stained with Giemsa. (D) Light-micrographs showing the typical appearance of 
tubules formed by control and pretreated ECFCs in Matrigel® (original magnification: x4).  (E) 
Comparison of the mean (± SEM) total length of tubules (% of control ECFCs) formed in 4 
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independent experiments. Results are normalized to untreated ECFCs. * p < 0.05, ** p < 0.01 
and *** p < 0.001, ### p < 0.001 compared to the  FGF2-stimulated ECFCs. 
 
Figure 3: The cell signalling induced by IL-34 in endothelial cells depends on cell surface 
glycosaminoglycans. Human ECFCs (A) and HUVECs (B-C) were treated with 200 ng/mL of 
IL-34 or M-CSF in the presence or absence of 5 ng/mL FGF-2 for 1 to 15 minutes (A, B) or for 
10 minutes (C). FAK, Akt, Src, ERK1/2 and p38 phoshorylations were analyzed by Western 
blot compared to the levels of GAPDH. (D) ECFCs were treated with 50 ng/mL of IL-34 in the 
presence of 5 ng/mL FGF-2 and 10 µM of signalling pathway inhibitors (PF 573228, a FAK 
inhibitor; PP2, a Src inhibitor; Wortmannin, a PI3K/Akt pathway inhibitor; UO126, an ERK1/2 
inhibitor. ECFCs were then seeded on Matrigel® in growth factor-depleted basal medium. After 
18h of culture the cells were fixed and stained with Giemsa. After 18h of culture, comparison 
of the mean (± SEM) total length of tubules (% of control ECFCs) formed in 3 independent 
experiments. Results are normalized to untreated ECFCs. (E) ECFCs were pretreated for 2 h at 
37°C with a mixture of 0.5 U/mL heparinase I, II and III, and 0.2 U/ml chondroitinases A, B, 
and C, for 30 min before 50 ng/mL IL-34 stimulation. Light-micrographs show the typical 
appearance of tubules formed by IL-34 pretreated ECFCs in Matrigel®, markedly reduced after 
enzymatic treatment (original magnification: x4). (F) Similar enzymatic treatment as described 
above abolishes the IL-34-induced signalling pathways in HUVECs. * p < 0.05, ** p < 0.01 
compared to the control condition (in absence of FGF2 and IL-34).  ## p < 0.001 compared to 
the FGF2+ IL-34 condition). 
 
Figure 4: IL-34 increases the recruitment of TAM and their differentiation toward M2 
phenotype. Human HOS osteosarcoma cells overexpressing IL-34 (HOS-IL34), M-CSF (HOS-
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MCSF) or transduced by the empty vector (HOS pLv105) were inoculated in close proximity to 
the tibia of female Rj:NMRI-nude mice (n=8 per group). All mice were sacrificed by cervical 
dislocation at an equivalent volume of 1500 mm3 and immunohistochemical assessment of 
IBA-1 and Arginase-1 was carried out.  (A) Total IBA-1+ macrophages infiltrate into the tumor 
mass. (B) M2 Arginase-1+ macrophage infiltrate in the tumours. The percentage of IBA-1 and 
Arginase-1 positive staining area was reported to the region of interest (R.O.I.) determined by 
ImageJ software (B). *p < 0.05 compared to the control HOS group. 
 
Figure 5: IL-34 significantly increases the adherence of monocytes to activated-
endothelium under shear stress conditions. Before flow perfusion, freshly isolated 
mononuclear cells were incubated for 30 min in RPMI 1640, 10% FCS, supplemented or not 
with 50 ng/mL IL-34, labelled with calcein and then perfused over a confluent HUVEC 
monolayer previously activated at a shear rate of 50s-1 according to the procedure described in 
Zemani et al.22. (A, B) Adhesion of treated mononuclear cells to HUVEC monolayer. Arrow: 
calcein-labelled mononuclear cells adherent to the HUVEC monolayer. (C) Fractions of 
adherent and tethering cells in each experimental group. (D) Differential adherence between 
IL-34-treated monocytes and control cells at shear rates up to 2500 s-1. Values are mean ± SEM 
of seven determinations. * p < 0.05, **p < 0.01, ***p < 0.001 compared to the untreated 
control group. 
 
Figure 6: IL-34 significantly increases the adherence of CD34
+
 cells to activated-
endothelium. CD34+ cells were incubated as described in Figure 5 and the results were 
compared to those of monocytes.  IL-34 treatment of CD34+ cells resulted in a further 2-fold 
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increase in cell adhesion on activated HUVECs, similar to monocytes (A-B). The effects on 
CD34+ stem cell tethering were comparable to those observed with monocytes (C-D). 
However, the resistance to detachment of IL-34-treated CD34+ cells was lower than with 
monocytes in the same experimental conditions (E-F). * p < 0.05; **p < 0.01; ***p < 0.001 
compared to the control group. 
 
  
Page 37 of 80 International Journal of Cancer
  
 
 
IL-34 promotes osteosarcoma growth, increases the number of lung metastases and the tumour vasculature 
in a mouse osteosarcoma model. Human HOS osteosarcoma cells overexpressing IL-34 (HOS-IL34), M-CSF 
(HOS-MCSF), transduced by the empty vector (HOS) were inoculated in close proximity to the tibia of 
female Rj:NMRI-nude mice (n=8 per group). (A) Follow-up of tumour volume for 27 days. (B) All mice were 
sacrificed by cervical dislocation at an equivalent volume of 1500 mm3 and the number of macroscopic lung 
metastases were scored manually. (C) immunohistochemical assessment of CD146 was carried out (Left 
Panel), and the percentage of CD146 positive vessel area was reported to the region of interest (R.O.I.) 
determined by ImageJ software (Right panel). *p < 0.05 compared to the control HOS group.  
107x76mm (300 x 300 DPI)  
 
 
Page 38 of 80International Journal of Cancer
  
 
 
IL-34 and M-CSF mediates the proliferation of endothelial colony-forming cells (ECFCs) and the tubule 
formation. (A-B) IL-34 and M-CSF induce ECFC proliferation in a dose-dependent manner after 48h of 
incubation. (C) IL-34 induces additive effect in the presence of FGF-2 after 24h of culture. (D-E) After 24h of 
culture in basal medium, in the presence or absence of 50 ng/mL IL34 and 100 ng/mL M-CSF, ECFCs were 
immediately seeded on Matrigel® in growth factor-depleted basal medium. After 18h of culture the cells 
were fixed and stained with Giemsa.. (D) Light-micrographs showing the typical appearance of tubules 
formed by control and pretreated ECFCs in Matrigel® (original magnification: x4).  (E) Comparison of the 
mean (± SEM) total length of tubules (% of control ECFCs) formed in 4 independent experiments. Results 
are normalized to untreated ECFCs. * p < 0.05, ** p < 0.01 and *** p < 0.001, ### p < 0.001 compared 
to the  FGF2-stimulated ECFCs.  
103x71mm (300 x 300 DPI)  
 
 
Page 39 of 80 International Journal of Cancer
  
 
 
The cell signalling induced by IL-34 in endothelial cells depends on cell surface glycosaminoglycans. Human 
ECFCs (A) and HUVECs (B-C) were treated with 200 ng/mL of IL-34 or M-CSF in the presence or absence of 
5 ng/mL FGF-2 for 1 to 15 minutes (A, B) or for 10 minutes (C). FAK, Akt, Src, ERK1/2 and p38 
phoshorylations were analyzed by Western blot compared to the levels of GAPDH. (D) ECFCs were treated 
with 50 ng/mL of IL-34 in the presence or absence of 5 ng/mL FGF-2 and 10 µM of signalling pathway 
inhibitors (PF 573228, a FAK inhibitor; PP2, a Src inhibitor; Wortmannin, a PI3K/Akt pathway inhibitor; 
UO126, an ERK1/2 inhibitor. ECFCs were then seeded on Matrigel® in growth factor-depleted basal medium. 
After 18h of culture the cells were fixed and stained with Giemsa. After 18h of culture, comparison of the 
mean (± SEM) total length of tubules (% of control ECFCs) formed in 3 independent experiments. Results 
are normalized to untreated ECFCs. (E) ECFCs were pretreated for 2 h at 37°C with a mixture of 0.5 U/mL 
heparinase I, II and III, and 0.2 U/ml chondroitinases A, B, and C, for 30 min before 50 ng/mL IL-34 
stimulation. Light-micrographs show the typical appearance of tubules formed by IL-34 pretreated ECFCs in 
Matrigel®, markedly reduced after enzymatic treatment (original magnification: x4). (F) Similar enzymatic 
treatment as described above abolishes the IL-34-induced signalling pathways in HUVECs. * p < 0.05, ** p 
< 0.01 compared to the control condition (in absence of FGF2 and IL-34).  ## p < 0.001 compared to the 
FGF2+ IL-34 condition).  
107x72mm (300 x 300 DPI)  
 
 
Page 40 of 80International Journal of Cancer
  
 
 
IL-34 increases the recruitment of TAM and their differentiation toward M2 phenotype. Human HOS 
osteosarcoma cells overexpressing IL-34 (HOS-IL34), M-CSF (HOS-MCSF) or transduced by the empty 
vector (HOS pLv105) were inoculated in close proximity to the tibia of female Rj:NMRI-nude mice (n=8 per 
group). All mice were sacrificed by cervical dislocation at an equivalent volume of 1500 mm3 and 
immunohistochemical assessment of IBA-1 and Arginase-1 was carried out.  (A) Total IBA-1+ macrophages 
infiltrate into the tumor mass. (B) M2 Arginase-1+ macrophage infiltrate in the tumours. The percentage of 
IBA-1 and Arginase-1 positive staining area was reported to the region of interest (R.O.I.) determined by 
ImageJ software (B). *p < 0.05 compared to the control HOS group.  
92x61mm (300 x 300 DPI)  
 
 
Page 41 of 80 International Journal of Cancer
  
 
 
IL-34 significantly increases the adherence of monocytes to activated-endothelium under shear stress 
conditions. Before flow perfusion, freshly isolated mononuclear cells were incubated for 30 min in RPMI 
1640, 10% FCS, supplemented or not with 50 ng/mL IL-34, labelled with calcein and then perfused over a 
confluent HUVEC monolayer previously activated at a shear rate of 50s-1 according to the procedure 
described in Zemani et al.22. (A, B) Adhesion of treated mononuclear cells to HUVEC monolayer. Arrow: 
calcein-labelled mononuclear cells adherent to the HUVEC monolayer. (C) Fractions of adherent and 
tethering cells in each experimental group. (D) Differential adherence between IL-34-treated monocytes and 
control cells at shear rates up to 2500 s-1. Values are mean ± SEM of seven determinations. * p < 0.05, 
**p < 0.01, ***p < 0.001 compared to the untreated control group.  
85x67mm (300 x 300 DPI)  
 
 
Page 42 of 80International Journal of Cancer
  
 
 
IL-34 significantly increases the adherence of CD34+ cells to activated-endothelium. CD34+ cells were 
incubated as described in Figure 5 and the results were compared to those of monocytes.  IL-34 treatment 
of CD34+ cells resulted in a further 2-fold increase in cell adhesion on activated HUVECs, similar to 
monocytes (A-B). The effects on CD34+ stem cell tethering were comparable to those observed with 
monocytes (C-D). However, the resistance to detachment of IL-34-treated CD34+ cells was lower than with 
monocytes in the same experimental conditions (E-F). * p < 0.05; **p < 0.01; ***p < 0.001 compared to 
the control group.  
158x174mm (300 x 300 DPI)  
 
 
Page 43 of 80 International Journal of Cancer
1 
 
Interleukin-34 promotes tumour progression and metastatic process in osteosarcoma 
through induction of angiogenesis and macrophage recruitment 
Aude Ségaliny1,2,#, Amel Mohammadi3,4,#, Blandine Dizier3,4, Anna Lokajczyk3,4, Régis Brion1,2,5, Rachel 
Lanel1,2, Jérôme Amiaud1,2, Céline Charrier1,2, Catherine Boisson-Vidal3,4,*, Dominique Heymann1,2,5,* 
 
1INSERM, UMR 957, Equipe LIGUE Nationale Contre le Cancer 2012, Nantes 44035, France 
2Université de Nantes, Nantes atlantique universités, Pathophysiology of Bone Resorption and 
Therapy of Primary Bone Tumours, Nantes, France 
3Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 
4INSERM, UMR 1140, Paris, France. 
5CHU de Nantes, France  
#AS and AM contributed equally to this work 
Running title: IL-34 promotes osteosarcoma progression 
Novelty & Impact Statements: IL-34 is a newly-discovered cytokine sharing a common 
receptor with M-CSF. IL-34 is expressed by osteosarcoma cells, regulated by TNF-α and IL-1β 
and is associated with an increase of osteosarcoma growth in bone site as well in the metastatic 
process as revealed by the higher number of lung metastases. In addition, IL-34 is a pro-
angiogenic factor in vitro and in vivo and promotes the recruitment of M2 macrophages into the 
tumour mass.  By promoting new vessel formation and extravasation of immune cells, IL-34 
may play a key role in the pathogenesis of osteosarcoma and in inflammatory diseases. 
*Corresponding authors: 
Prof. Dominique Heymann 
INSERM UMR 957, Faculty of Medicine,  
1 rue Gaston Veil, 44035 Nantes cedex, France 
Phone: 33 (0) 272 641 132; Fax: 33 (0) 240 412 860 
E-mail: dominique.heymann@univ-nantes.fr 
 
Dr Catherine Boisson-Vidal 
INSERM UMR 1140, Faculty of Pharmacy 
4 av. de l’Observatoire, 75006 Paris, France.  
Phone: 33 (0) 153 739 716, fax 33 (0) 144 071 772.  
E-mail: catherine.boisson-vidal@parisdescartes.fr 
  
Page 44 of 80International Journal of Cancer
2 
 
ABSTRACT 
Interleukin-34 (IL-34) was recently characterized as the M-CSF “twin” cytokine, regulating the 
proliferation/differentiation/survival of myeloid cells.  The implication of M-CSF in oncology 
was initially suspected by the reduced metastatic dissemination in knock-out mice, due to 
angiogenesis impairment. Based on this observation, our work studied the involvement of IL-
34 in the pathogenesis of osteosarcoma. The in vivo effects of IL-34 were assessed on tissue 
vasculature and macrophage infiltration in a murine preclinical model based on a paratibial 
inoculation of human osteosarcoma cells overexpressing or not IL-34 or M-CSF. In vitro 
investigations using endothelial cell precursors and mature HUVEC cells were performed to 
analyse the involvement of IL-34 in angiogenesis and myeloid cell adhesion. The data revealed 
that IL-34 overexpression was associated with the progression of osteosarcoma (tumour 
growth, lung metastases) and an increase of neo-angiogenesis. In vitro analyses demonstrated 
that IL-34 stimulated endothelial cell proliferation and vascular cord formation. Pre-treatment 
of endothelial cells by chondroitinases/heparinases reduced the formation of vascular tubes and 
abolished the associated cell signalling. In addition, IL-34 increased the in vivo recruitment of 
M2 Tumour Associated Macrophages into the tumour tissue. IL-34 increased monocyte/CD34+ 
cell adhesion to activated HUVEC monolayers under physiological shear stress conditions. 
This work demonstrates that IL-34 is expressed by osteosarcoma cells, is regulated by TNF-α, 
IL-1β and contributes to osteosarcoma growth by increasing the neo-angiogenesis and the 
recruitment of M2 macrophages. By promoting new vessel formation and extravasation of 
immune cells, IL-34 may play a key role in tumour development and inflammatory diseases. 
 
Key words:  Interleukin-34, M-CSF, Endothelial cells, Angiogenesis, Cell adhesion, Tumour 
Associated Macrophages, Osteosarcoma 
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INTRODUCTION 
 
Angiogenesis and vasculogenesis are central events during embryogenesis and growth [1, 2]. 
They are also strongly implicated in the pathogenesis of inflammation, by promoting immune 
cell extravasation, and of cancer, by facilitating tumour initiation and development [3]. 
Numerous publications underscore the possible contribution in the biological mechanisms of 
the Macrophage-Colony Stimulating Factor (M-CSF), a cytokine required for the survival and 
differentiation of mononuclear phagocytic cell lines derived from monocytes such as 
macrophages and dendritic cells [4,5]. Monocytes migrate to the tumour foci attracted by the 
chemokines / cytokines produced by tumour cells. Once activated, macrophages are the main 
source of growth factors and cytokines [6]. Thus, Curry et al. reported that M-CSF induced the 
expression of VEGF from human monocytes and consequently stimulates the angiogenic 
process [7]. The tumour-associated macrophages (TAMs) significantly contribute to tumour 
growth and metastasis and are associated with poor prognosis in various forms of cancer. 
Indeed, they exert tropic roles and promote growth, angiogenesis and tumour cell motility [6, 
8]. Based on these data, the infiltrate of mononuclear phagocytes, M-CSF, VEGF and 
angiogenesis are correlated with poor prognosis in various solid cancers [9, 12]. 
 
In 2008, a new cytokine named interleukin-34 (IL-34) was discovered by Lin et al. 
based on its ability to form colony-forming unit–macrophages in human bone marrow cultures, 
with the same efficiency as M-CSF [13]. They demonstrated the binding of IL-34 to the M-CSF 
receptor (CSF-1 receptor or c-fms) expressed on human mononuclear phagocytes. More 
recently, Wang et al. reported that IL-34 was a specific driver of myeloid cell differentiation in 
the skin epidermis and central nervous system [14]. IL-34 also directs the differentiation of 
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monocytes into immunosuppressive M2 similar to M-CSF [15]. In addition, we demonstrated 
the role of IL-34 in promoting osteoclastogenesis in which this cytokine can be a substitute for 
M-CSF [16]. IL-34, like M-CSF, upregulates the chemokines produced by whole blood, 
identifying both cytokines as key partners in inflammation [17]. The role of IL-34 was 
confirmed in rheumatoid arthritis where the cytokine levels were significantly higher in the 
synovial fluids of RA patients compared with osteoarthritis patients and were correlated with 
inflammation intensity measured by the leucocyte number [18]. IL-34 shares common features 
with M-CSF, partly explaining their functional overlaps, and can be considered with M-CSF as 
“twin” cytokines that are functionally related [19]. 
 
Based on the role of IL-34 in the differentiation of mononuclear phagocytes and in 
inflammation, the present manuscript aimed to analyse the potential involvement of IL-34 in 
pathogenesis of osteosarcoma. This work focused on the role of IL-34 in the neo-angiogenesis 
and macrophage recruitment associated with tumour development. 
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MATERIALS AND METHODS 
Reagents 
Recombinant Interleukin-34 (IL-34), Macrophage-Colony Stimulating Factor (M-CSF), Tumor 
Necrosis Factor-α (TNF-α), IL-1β and basic fibroblast growth factor (FGF-2) were obtained 
from R&D Systems (Abingdon, UK). Growth factor-reduced Matrigel® was from Becton 
Dickinson (Le Pont de Claix, France). Wortmannin (PI3K inhibitor) was purchased form 
Calbiochem (France), PF573228 (FAK inhibitor) from Santa Cruz (France), PP2 (Src kinase 
inhibitor) from Abcam (France) and U0126 (ERK1/2 inhibitor) from Promega (France). Cell 
culture products and other biochemical reagents were purchased from Sigma-Aldrich (Saint 
Quentin Fallavier, France) unless otherwise specified.  
 
Tissue specimens 
Patient tumour biopsy specimens were collected at Nantes University Hospital (Nantes, France) 
(Supplementary Data 1). Samples were obtained following patient informed consent, and after 
ethical approval by the Nantes University Hospital Ethics Committee.  
 
Cell characterization, culture and treatment 
Umbilical cord blood samples were collected from consenting mothers (n=20). The study was 
approved by the ethics committee of the Hôpital des Instructions et des Armées de Begin 
(France) (ref. 201008043234797), and the protocol conformed to the Declaration of Helsinki. 
Endothelial cells from human umbilical cords (HUVECs) and endothelial colony-forming cells 
(ECFCs) from human umbilical cord blood were isolated, expanded and characterized as 
previously described [20]. The presence of Weibel-Palade bodies, combined expression of 
endothelial markers (CD31, KDR, Tie-2, CD144), and dual positivity for DiI-AcLDL uptake 
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and BS-1 lectin binding confirmed the endothelial phenotype of the ECFCs thus obtained. 
ECFCs do not express leukomonocytic markers such as CD45 and CD14 [121. One day before 
the experiments, the cells were growth-arrested for 18 h in EBM2, 2 % FCS (starvation 
medium) and released from growth arrest by adding EBM2, 5 % FCS (basal medium), with or 
without 50 ng/mL of IL-34 or 100 ng/mL M-CSF in the presence or absence of FGF-2 (5 
ng/mL) at 37°C. Cells were then washed, detached with PBS-EDTA or trypsinized at 37°C, 
and washed twice with PBS before use. All assays were performed at least in triplicate, with 
cells cultured for less than 30 days. In some cases, ECFCs were pretreated for 2 h at 37°C with 
a cocktail of heparinase I, II and III (0.5 U/mL) and 0.2 U/ml chondroitinases A, B and C, for 1 
hour at 37°C, then extensively washed with PBS before IL-34 stimulation.  
 
In vitro angiogenesis assays 
To investigate the effects of IL-34 and M-CSF on ECFC adhesion, proliferation and tubular 
morphogenesis, ECFCs were stimulated as described above. Cell outgrowth, adhesion and in 
vitro tube formation were evaluated as previously described [20]. To assess, the effects of 
pharmacology inhibitors on the tubular network formation, ECFCs were pre-treated with 
inhibitors of FAK (PF 573228), Src (PP2) PI3K.Akt pathway (Wortmannin) and ERK-1/2 
(U0126). Each inhibitor was added to ECFC 30 minutes prior to each treatment according to 
manufacturers’ instructions and maintained all along the time of culture and before to add 50 
ng/mL of IL-34. Pharmacological inhibitors were dissolved in dimethyl sulfoxide (DMSO) and 
the final concentration of DMSO in samples was less than 0.2 % (1/1000). In preliminary 
experiments, no significant influence of solvents on cell proliferation and morphology was 
observed. 
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Monocytes and CD34
+
 cell isolation from human peripheral blood 
Mononuclear cells were isolated by density-gradient centrifugation from fresh peripheral blood 
mononuclear cells collected from healthy donors provided by the French blood bank institute 
(EFS) under an agreement with Paris Descartes University (C CPSL UNT n°12/EFS/064). 
Monocytes were isolated with the Monocyte Isolation Kit II (MACS Miltenyi Biotec, Paris, 
France) by negative selection. 
 
Shear-flow adhesion assays 
Flow adhesion experiments were conducted with a parallel-plate chamber in physiological 
shear stress conditions as previously described [22, 23]. Briefly, calcein-labelled freshly 
isolated monocytes/CD34+cells (3x106) were perfused on activated HUVEC monolayers for 15 
min at 37°C at a shear rate of 50 s-1. Cell adhesion was dependent on endothelial activation and 
on the shear rate, as it was optimal at shear rates below 350 s-1, whereas far fewer cells adhered 
at 500 s-1. Adherent cells were visualized by phase-contrast microscopy. All experiments were 
observed in real-time and videotaped for offline analysis. Fluorescence micrographs of 40 
random microscopic fields (obj. x10, 1 cm2) were collected with Replay software (Microvision 
Instruments, France). Data were expressed as the number of adherent cells per field. The 
results of 4 different experiments were pooled for each study. The pattern of adhesion at 50 
sec-1 was also analyzed to determine the number of tethering cells and adherent cells 
(immediate full arrest). Adherent monocytes were tested for resistance to detachment from the 
modelled endothelium by increasing the flow rate from 50 to 5000 s-1 over 1 minute, and by 
counting the number of remaining adherent cells at one-minute intervals. 
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Murine Matrigel
®
 plug assay 
Animal care conformed to French guidelines (Services Vétérinaires de la Santé et de la 
Production Animale, Ministère de l’Agriculture, Paris France) and experiments were in 
agreement with the guidelines of the University Paris-Descartes Institutional Animal Care and 
Use Committee (C75.06.02). Ice-cold Matrigel® (BD, 8 mg/ml) was mixed with phosphate-
buffered saline (PBS) plus FGF2 (350 ng/ml) alone or supplemented with 500 ng/ml of IL34 or 
M-CSF, then injected subcutaneously into male C57BL/6J mice (8 weeks old, from Elevages 
Janvier, France). The Matrigel® plugs were recovered 14 days later. Haemoglobin content was 
measured with Drabkin’s reagent (Sigma). Functional vessels were identified by light 
microscopy as vessels containing red blood cells. 
 
Western Blot Analysis 
ECFCs or HUVECs treated with 200 ng/mL of IL-34 or M-CSF for 1 to 15 min. The proteins 
obtained form the cell lysates were separated by SDS-PAGE and transferred to immobilon-P 
for Western blot.  The membranes were blotted with the antibodies (1/1000) anti-pFAK 
(Tyr925), anti-pAkt (Ser473), anti-pSrc (Tyr416), anti-p38 (Thr180/Tyr182), anti-pERK 1/2 
(Thr202/Tyr204), or with antibodies against the total forms of protein above (Cell Signalling, 
Danvers, MA, USA). The membrane was probed with the secondary antibody (1/10000) 
coupled to horseradish peroxidase. Antibody binding was then visualized with an ECL kit 
(Pierce Protein Biology Products, Thermo Scientific Rockford, USA). The luminescence 
detected with a Charge Couple Device (CCD) camera was quantified using the GeneTools 
programme (Syngene, Cambridge, United Kingdom). 
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Lentivirus production and osteosarcoma cell transduction  
Vector pEZ-Lv105 (GeneCopoeia, Rockville, USA) containing either the human IL-34 gene 
(Accession Number BC029804) or the human M-CSF gene (Accession number NM_000757) 
were used to produce lentiviral particles. The pEZ-Lv105-eGFP (GeneCopoeia) was used as a 
control. Lentivirus were produced using packaging vectors as described by Dull et al.24 Briefly, 
6 x106 HEK293FT cells (human embryonic kidney cells optimized for viral production) were 
seeded and transfected 24 h later with 3 µg of each packaging plasmid (pLP-1, pLP-2 and pLP-
VSV-G) and 9 µg of the transgene of interest (pEZ-Lv105-eGFP, pEZ-Lv105-M-CSF or pEZ-
Lv105-IL-34); virus-containing supernatants were collected 48 h post-transfection and 
concentrated 60-fold by ultrafiltration. For titration, serial dilutions of virus containing 
supernatants were tested on HEK293FT cells that were analyzed for EGFP expression 4 days 
post-infection by flow cytometry (FACSCalibur Flow cytometer, BD Biosciences, Le Pont de 
Claix, France). The titres obtained were between 10x106 and 10x107 viral particles/µL. Human 
osteosarcoma KHOS/NP (HOS), U2OS, Saos2 and MG63 cells purchased from the ATCC 
(USA) were cultured in DMEM (Lonza, Belgium) supplemented with 5% of Foetal Bovine 
Serum (FBS; Hyclone Perbio, France). To generate stably modified HOS cell lines, 2x104 HOS 
cells were seeded in a 24-well plate in 300 µl medium and infected with a multiplicity of 
infection of 10 particles/cell. After transduction, the cells expressing the transgene were 
selected at confluence with 2µg/mL puromycin (Sigma, France) to obtain a stable population. 
The eGFP, M-CSF and IL-34 expression levels were controlled by flow cytometry analysis for 
eGFP and IL-34 (R&D), ELISA for M-CSF (R&D) and also RT-qPCR (Supplementary Data 
1A,B). 
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RNA isolation and real-time PCR 
Total RNA was extracted using NucleoSpin®RNAII (Macherey Nagel, Duren, Germany) with 
one stage of DNase I treatment (25 units, 15 min) to prevent genomic contamination. 1 µg of 
total RNA was used for first strand cDNA synthesis using the ThermoScript RT-PCR System 
(Invitrogen). Real-time PCR was performed on 20 ng of reverse transcribed total RNA 
(cDNA), 300 nM of primers and 2x SYBR Green Supermix (Biorad, Marnes-la-Coquette, 
France). Quantitative PCRs (qPCR) were carried out on a Bio-Rad CFXTM System (Biorad). 
Analyses were performed using human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
orhuman hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1) as invariant controls. 
The sense and antisense primers used are as follow: human HPRT1 (forward: 
TGACCTTGATTTATTTATTTTGCATACC, reverse: CGAGCAAGACGTTCAGTCCT); 
human GAPDH (forward: TGGGTGTGAACCATGAGAAGTATG, reverse : 
GGTGCAGGAGGCATTGCT) ; human IL-34 (forward: AATCCGTGTTGTCCCTCTTG, 
reverse: CAGCAGGAGCAGTACAGCAG); human M-CSF (forward: 
GTTTGTAGACCAGGAACAGTTGAA, reverse CGCATGGTGTCCTCCATTAT). 
 
Confocal microscopy  
Osteosarcoma cells were cultured in a plastic chamber on microscope glass slides (Millicell EZ 
Slide, Millipore, Billerica, MA, USA) were stimulated or not with 10 ng/mL of TNF-α or IL-
1β for 24 h. The cells were then washed in PBS, fixed in 4% paraformaldehyde for 10 min at 
room temperature, permeabilized with triton X-100 0.1% for 20 min and incubated with a 
blocking solution [BSA 1% with 1% of non-immune goat serum (Dako, Les Ulis, France) and 
0.05% triton] for 30 min at room temperature. The cells were incubated with either the primary 
antibody against IL-34 (Diaclone, INSERM UMR 957) or the blocking solution as the negative 
control for 90 min at 37°C. After washings, Alexa Fluor 488 secondary antibody (1/200) was 
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added for 90 min at room temperature. Actin filaments were stained using 546-conjugated 
phalloidin (1/300) and nuclei stained with DAPI (1/5000).  
 
Osteosarcoma mouse model 
The mice (Elevages Janvier, Le Genest Saint Isle, France) were housed in pathogen-free 
conditions at the Experimental Therapy Unit (Faculty of Medicine, Nantes) in accordance with 
the institutional guidelines of the French Ethical Committee (CEEA PdL 06 ethical committee, 
authorization number: 1280.01) and under the supervision of the authorized investigators. Five-
week-old female Rj:NMRI-nude mice (n=8 per group) were anaesthetized by inhalation of an 
isoflurane/air mixture (2%, 1L/min) before i.m. inoculation of 1.5x106 human HOS 
osteosarcoma cells over-expressing M-CSF, IL-34 or transduced by the empty vector. 
Osteosarcoma cells were injected in close proximity to the tibia, rapidly leading to tumour 
growth in the soft tissue with secondary contiguous bone invasion [25]. Tumours appeared at 
the injection site 8 days later and their volumes were calculated for 27 days by measuring two 
perpendicular diameters using calipers, according to the following formula: V = 0.5 x L x (S)2, 
in which L and S are, respectively, the largest and the smallest perpendicular diameters as 
previously described [25]. To determine the effect of IL-34 in the formation of lung metastases, 
mice were sacrificed by cervical dislocation at an equivalent volume of 1500 mm3. Lung 
metastases were macroscopically and manually scored in each animal. The overexpression of 
M-CSF or IL-34 in explanted tumour tissues established from inoculation of M-CSF- or IL-34-
transduced HOS osteosarcoma cells was validated by RT-qPCR (Supplementary Data 1C). 
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Immunohistochemistry 
After euthanasia, tumour samples were preserved and fixed in 10% of PFA, decalcified with 
4.13% of EDTA, and 0.2% of PFA in PBS using a microwave tissue processor (KOS, Mikron 
Instruments, USA) for 4 days and embedded in paraffin. Three micrometer sections were then 
stained for mouse CD146 (Abcam, 1/200), mouse CD31 (Abcam, 1/100) [25], mouse ionized 
calcium-binding adapter molecule 1 (IBA-1, Abcam, 1/700) or mouse arginase-1, (BD 
Biosciences, 1/500). IL-34 was detected as previously described by Chemel et al [18]. Images 
were automatically numerized (nanozoomer, Hamamatsu photonics) before quantification. The 
negative control was analysed using a similar procedure, excluding the primary antibody and 
using a normal rabbit-irrelevant IgG at 1/100 (R&D Systems). The image analysis was 
performed on the whole tumour sections with FIJI (ImageJ), the region of interest (R.O.I.) 
excluding necrotic tissue and the skeletal muscle. The percentage of CD146, IBA-1 or Arg-1 
positive cell surfaces was quantified after a DAB colour deconvolution function, using the pixel 
density of the red staining, and reported to the R.O.I. selected.  
 
Statistical analysis 
Differences between in vitro experimental conditions were assessed with Student’s t test or 
one-way ANOVA followed by the Mann–Whitney test. In vivo results were analyzed using a 
non-parametric one-way analysis of variance followed by a Dunn’s post-hoc test using 
GraphPad InStat v3.02 software. The results are given as a mean ± SEM of at least three 
independent experiments. Results were considered significant at p values ≤ 0.05. 
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RESULTS 
IL-34 is expressed by osteosarcoma cells, promotes osteosarcoma progression and 
increases the establishment of lung metastases 
The expression of IL-34 was first analysed by qPCR in 12 biopsies of human osteosarcomas 
(Supplementary Data 2A). The results clearly demonstrated that all osteosarcoma tissues 
expressed IL-34 (Supplementary Data 2B) with apparent heterogeneous expression levels. In 
addition, our data were validated in a cohort of 27 osteosarcoma biopsies described by Dr 
Yamada from the National Cancer Center of Tokyo [26] (GEO Series GSE14827) in which all 
osteosarcoma samples expressed IL-34 (Supplementary Data 2C, D). The expression of IL-34 
was next assessed in 4 human osteosarcoma cell lines (HOS, U2OS, SaoS2, MG63) and was 
demonstrated in all cell lines studied (Supplementary Data 2B). We next assessed the 
expression of IL-34 by various osteosarcoma cells in vitro and its regulation by TNF-α and IL-
1β. IL-34 messenger RNA was detectable in non-stimulated cells. Stimulation with TNF-α and 
IL-1β resulted in a significant dose-dependent induction of IL-34 mRNA (Supplementary Data 
3A). Confocal microscopy analyses confirmed that TNF-α and IL-1β upregulated the 
expression of IL-34 by osteosarcoma cells at the protein level compared to untreated cells 
(Supplementary Data 3B).  IL-34 expression was then analyzed by immunohistochemistry in 
human osteosarcoma biopsies. In all samples studied, most of osteosarcoma cells exhibited a 
positive nuclear and/or cytoplasmic immunostaining for IL-34  (Supplementary data 4A-D). As 
previously observed for giant cell tumours of bone, multinucleated cells also expressed IL-34 
staining (Supplementary Data 4A) [16] in contrast to osteocytes which were negative 
(Supplementary Data 4B).  
To determine the potential involvement of IL-34 in the pathogenesis of osteosarcoma, 
human HOS osteosarcoma cell line expressing a very low level of IL-34 (Supplementary Data 
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2B), was genetically modified to overexpress the corresponding cytokine. The volume of the 
tumours induced in Nude mice by the different cell line generated was then compared (Figure 
1A). IL-34 overexpression increased significantly the tumour progression compared to the 
control groups (non transduced cells and HOS cells transduced with an empty vector) (p < 
0.001). Indeed, the mean tumour size of established tumours from IL-34-overexpressing HOS 
cells (2131 +/- 392 mm3) was 57% higher compared to control group (1359 +/- 146 mm3 for 
the empty vector transduced HOS cells (Figure 1A). Similarly, the progression of the tumours 
induced by M-CSF-transduced HOS cells was significantly upmodulated compared to the 
control groups (at day 27, tumour volumes: 1805 +/- 218 mm3 for the M-CSF group, compared 
to 1201 +/- 180 mm3 for the non transduced control group, p < 0.01) (Figure 1A).  Because 
osteosarcoma cells exhibit a high ability to induce lung metastases, we compared the number of 
lung metastases formed with the different cell lines generated (Figure 1B). Interestingly, at an 
equivalent volume of primary tumours (1500 mm3), the number of lung metastases formed in 
groups overexpressing IL-34 and M-CSF were significantly higher than in the control groups (p 
< 0.05 and p < 0.001 respectively) (Figure 1B). Overall, these data reveal that IL-34 and M-
CSF promote osteosarcoma development and facilitate the lung metastatic process.  
 
IL-34 upmodulates the formation of neo-vessels in HOS mouse osteosarcoma  
To examine the mechanisms underlying the effect of IL-34 and M-CSF on tumour progression, 
histopathological investigations were carried out on the tumour tissues.  At the endpoint of the 
experiment (tumour size: 1500 mm3), CD146+ vessels into the tumour mass were assessed by 
immunohistochemistry (Figure 1C). The density of neo-vessels was significantly increased in 
tumours over-expressing IL-34 compared to the control group (Figure 1C, p<0.05). CD31 
showed similar patterns of expression strengthening the pro-angiogenic effect of IL-34 
(Supplementary Data 5). M-CSF over-expressing HOS cells exhibited a slight but not 
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significant increase in the CD146+ and CD31+ vessels (Figure 1C, Supplementary Data 5). To 
confirm the pro-angiogenic effect of IL-34 in vivo, we used an in vivo Matrigel® plug assay, a 
non tumour model. As shown in Supplementary Data 6, plugs from the PBS control group and 
plugs containing M-CSF alone were mostly translucent and pale, indicating little or no vessel 
formation after two weeks. In contrast, plugs containing FGF-2 and IL-34 alone were redder, 
indicating the very early stages of a vasculature. However, plugs containing IL-34 and FGF-2 
together had a modest non-stimulatory effect on angiogenesis compared to FGF-2 alone. IL-34 
alone was able to recruit endothelial cells to form vascular structures within the Matrigel® 
plugs. In addition, plugs treated concurrently with FGF-2 and M-CSF had an intense red 
colour, indicating the presence of abundant new capillary vasculature formation. An analysis of 
haemoglobin content confirmed that FGF-2 and M-CSF together enhanced neo-angiogenesis 
compared to M-CSF alone (Supplementary Data 6). Thus, M-CSF appeared to enhance the 
FGF-2-induced recruitment of circulating cells, suggesting a synergistic effect on angiogenesis 
in vivo. These data demonstrate that IL-34 is a pro-angiogenic factor in vivo and suggest its 
implication in tumour development. 
 
IL-34 induces tubular morphogenesis of ECFCs in Matrigel
®
 and its activity depends on 
cell surface glycoaminoglycans 
We next explored in vitro the mechanistic effect of IL-34 in endothelial cells. We first focused 
our work on ECFCs because this cell type is currently proposed as the cell type at the origin of 
newly-formed vessels. Proliferation was examined by measuring cell phosphatase activity 
based on the release of pNPP measured after 48 h of incubation in basal medium (EBM2, 5% 
FCS) containing IL-34 or M-CSF. IL-34 clearly demonstrated a bell-shaped response curve 
with optimum proliferation occurring at 50 ng/mL (p<0.01) and an inhibitory activity at high 
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doses (Figure 2A) whereas M-CSF enhanced ECFC proliferation in a concentration-dependent 
manner, starting at 6 ng/mL after 48h of incubation (Figure 2B). IL-34 induces an additive 
effect to enhance cell proliferation, in the presence of FGF2 (p<0.01 versus FGF-2 alone, 
Figure 2C).    
ECFCs were incubated overnight in starvation medium (EBM2 + 2.5% FCS) then 
stimulated for 24h with IL-34 or M-CSF in basal medium (EBM2 + 5% FCS), with or without 
FGF-2 before seeding on Matrigel® for 18h. Without FGF-2 pretreatment, ECFC did not form 
any tubular structures, even in the presence of 50 ng/mL IL-34 and 100 ng/mL M-CSF, 
remaining as individual cells or small aggregates (Figure 2D). In contrast, 18h after seeding, 
pretreatment with FGF-2 promoted ECFC organization into branched structures and 
pseudotubes with enclosed areas (p<0.01) (Figure 2E). The tubular network was significantly 
more extensive in the presence of 50 ng/mL IL-34 (1.3 fold increase, p<0.001) or 100 ng/mL 
M-CSF (1.8 fold increase, p<0.001) and 5 ng/mL FGF2 compared to the FGF2 alone.  
This effect is associated with the activation of signalling pathways in ECFCs and in 
HUVECs (Figure 3, Supplementary Data 7). In ECFCs, IL-34 rapidly induced the 
phosphorylation of FAK and ERK1/2 compared to the non-treated cells, in contrast to Akt and 
Src phosphorylations that were slightly modulated (Figure 3A, Supplementary Data 7). In 
HUVECs, IL-34 increased mainly the phosphorylation of Src, FAK (Figure 3B, Supplementary 
Data 7) and p38 (Figure 3C, Supplementary Data 7). M-CSF induced differential modulations 
of signalling pathways in EFCFs compared to IL-34 as shown for P-FAK. Indeed, in ECFCs, P-
FAK was not modulated in the presence of M-CSF in contrast to IL-34 (Figure 3A, 
Supplementary Data 7). In HUVECs, M-CSF induced similar patterns of phosphorylation 
compared to IL-34 (P-FAK, P-Src and P-p38) (Figure 3). As expected, FGF-2 increased the 
phosphorylations of p38, Src, ERK1/2 and the addition of M-CSF did not modify the response 
of FGF2 (Figure 3C). P-38 and P-Src induced by FGF-2 were slightly decreased by addition of 
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IL-34 (Figure 3C).  To evaluate the functional involvement of the signaling pathways that 
could be involved in IL34 effect on tubular morphogenesis of ECFC on matrigel, cells were 
cultured in the absence or presence of IL34 and different protein kinase inhibitors: PI3K/Akt 
inhibitor Wortmannin; Src inhibitor PP2; ERK1/2 inhibitor UO126; and FAK inhibitor 
PF573228 (Figure 3D). As expected, IL-34 and FGF2 induced an additive effect for increasing 
the formation of vascular tubes. Src and ERK1/2 inhibitors (PP2 and UO126 respectively) 
abolished the formation of vascular tubes compared to the control group (P < 0.001). FAK and 
Akt inhibitors (PF 573228 and Wortmannin) also suppressed the cytokine effects (Figure 3D, p 
< 0.01 compared to the FGF2+IL34 group). These results support that these 4 protein kinases 
(PI3K, Src, FAK and ERK) play a key role in the effect of IL-34 on cell differentiation into 
vascular cords. 
As revealed by RT-qPCR, ECFCs and HUVECs did not express the M-CFR (data not 
shown). Consequently the IL-34 induced signalisation in endothelial cells appears M-CSFR-
independent in the culture conditions used.  Because glycosaminoglycans are strongly involved 
in the biology of endothelial cells, we investigated their involvement in IL-34-induced 
angiogenesis (Figures 3E, 3F). The pretreatment of HUVECs by a cocktail of enzymes 
composed by chondroitinases and heparinases resulted in a disorganization of branched 
structures and pseudotubes formed in Matrigel® (Figure 3E). In addition, the abrasion of 
glycosaminoglycans strongly inhibited the FAK and Src phosphorylations induced by one 
minutes of IL-34 treatment and led to the dephosphorylation of both proteins after 5 minutes of 
IL-34 treatment (Figure 3F). Overall, these data strengthen the implication of 
glycosaminoglycans in IL-34-induced angiogenesis. 
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IL-34 promotes the recruitment of M2 TAM in osteosarcoma 
Given the involvement of IL-34 in osteosarcoma tumour growth and its ability to induce, in 
vitro, the differentiation of human monocytes into immunosuppressive macrophages [15], we 
investigated by immunohistochemistry the populations of osteosarcoma-associated 
macrophages. As shown in Figure 4, HOS osteosarcoma was moderately infiltrated by 
macrophages revealed by IBA-1 staining. Interestingly, IL-34-overexpressing tumours exhibit a 
three-fold increase of the IBA-1 positive TAMs compared to the control group (Figure 4A, p < 
0.01) whereas M-CSF-overexpressing tumours showed a slight but non significant increase of 
TAM number. We then investigated the infiltration of M2 macrophages by arginase-1 
expression (Figure 4B). The number of Arginase-1 macrophages was markedly increased in the 
tumour tissue formed by IL-34- and M-CSF-transduced cells compared to the control group [a 
5- (p < 0.05) and 6- (p < 0.01) fold increase for M-CSF and IL-34 respectively compared to the 
empty vector-trasnduced HOS cells, Figure 4B]. These data demonstrate that IL-34 promotes 
the recruitment of M2 macrophages in osteosarcoma. 
 
IL-34 pre-conditioning promotes monocyte/CD34
+
 adhesion to activated HUVEC 
monolayers under physiological shear stress conditions 
We next investigated whether IL-34 had a direct effect on monocyte adhesion to the 
endothelium, under physiological flow conditions. Freshly isolated monocytes were stimulated 
for 30 min with 50 ng/mL in medium supplemented with 5% FCS, prior to adhesion. We used a 
flow-based adhesion assay using HUVEC monolayers to investigate the binding of cytokine-
stimulated monocytes to an activated endothelium. The experimental conditions mimicked the 
shear forces encountered by cells adhering to vascular endothelial cells in vivo. As shown in 
Figures 5A-B, incubation of monocytes with recombinant IL-34 significantly increased the 
percentage of adherent monocytes (163% versus 100% control after 10 min; p<0.05), an effect 
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similar to that observed with SDF-1 pre-treatment [22]. IL-34 pre-treatment increased the rate 
of cell tethering to the activated modelled endothelium by about 50% at a shear rate of 50sec-1 
(Figure 5C). In addition, IL-34-stimulated monocytes adhered more strongly and were more 
resistant to washing than control untreated cells, at shear rates up to 2500 s-1 (Figure 5D). A 
similar experiment was carried out on CD34+ cells and the results were compared to those of 
monocytes. Il-34 treatment of CD34+ cells resulted in a further 2-fold increase in cell adhesion 
similarly to monocytes (p<0.001, Figures 6A-B) (Supplementary Video 1, Supplementary 
Video 2). The effect on CD34+ stem cell tethering was comparable to that observed with 
monocytes (Figure 6C-D). However, the resistance to detachment of IL-34-treated CD34+ cells 
was lower than with monocytes in the same experimental conditions (Figures 6E-F) 
(Supplementary Video 3, Supplementary Video 4). 
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DISCUSSION 
Inflammation is a key biological process enabling the tissues to develop a host defense 
mechanism to injury, infectious agents, cancers or immune dysregulation. It is now recognized 
that endothelial cells play a central role in these mechanisms [27]. The inflammatory 
environment is effectively characterized by an enrichment of immune cells (neutrophils, 
eosinophils, mast cells, NK cells, macrophages, dendritic cells and lymphocytes) that promote 
angiogenesis by releasing pro-angiogenic factors and by remodelling the extracellular matrix, 
allowing blood vessel formation [28]. In return, endothelial cells from neo-vessels increase the 
inflammation by recruiting immune cells locally, facilitate their extravasation and macrophage 
polarization [29]. In addition, the hypoxia environment exacerbates this phenomenon [30]. 
The present data demonstrated that osteosarcoma cells express IL-34. Osteosarcoma 
cells originate from a mesenchymal stem cell committed toward osteoblastic differentiation 
[31].  Previous works showed that IL-34 was produced in bone marrow [32] and in osteoblasts 
[33] and that expression was increased by inflammatory cytokines such as TNF-α and IL-
1β [18, 33]. Similarly, TNF-α and IL-1β upmodulated the expression of IL-34 in osteosarcoma 
cell lines. It is admitted that an inflammatory environment is established during the tumour 
development. In this context, the IL-34 production by osteosarcoma cells (as shown in human 
biopsies) would facilitate the formation of blood vessels and the macrophage infiltration by 
modifying the tumour microenvironment. The present work shows that IL-34 exerts pro-
angiogenic function both in vitro and in vivo and for the first time that IL-34 can regulate the 
proliferation of endothelial colony-forming cells. IL-34 modulated FAK, Src, Akt and ERK1/2 
signaling pathways in endothelial cells and as expected these signal molecules appeared critical 
for appears for IL-34-mediated angiogenesis. Indeed, FAK is a key mediator of integrin 
signaling as well as important components of signaling by numerous surface receptors and 
FAK knockout mice models demonstrated its critical role critical role of FAK in angiogenesis 
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during embryonic development and cancer progression [34-35]. FAK was found to mediate Src 
phosphorylation [36] and consequently Scr modulates endothelial phenotype and angiogenesis 
[37, 38]. Similarly, Akt and ERK1/2 play critical roles in the regulation of endothelial cells and 
vascular homeostasis [39, 40]. In addition, activation of both ERK1/2 and PI3K is required for 
inducing a complete cell proliferation of endothelial cells in response to FGF2 [41]. Our data 
are in agreement with those published by Emese et al. revealing a potential role of IL-34 in 
angiogenesis associated to inflammatory arthritis [42]. The indirect role of M-CSF in 
angiogenesis has already been reported by its ability to recruit mononuclear phagocytes that 
increase VEGF levels [7] or by the induction of systemic VEGF from skeletal muscles [43]. 
Based on the present data, and similar to M-CSF, IL-34 exhibits direct effects on endothelial 
cells. IL-34 effectively activates the signalling pathway in endothelial cells, and controls their 
proliferation and the formation of pseudotubes in vitro and in Matrigel® plugs in vivo. In 
addition, in absence of M-CSFR, the pro-angiogenic activity of IL-34 required the presence of 
glycosaminoglycans. Heparan sulfate and chondroitin sulfate influence multiple cellular 
properties such as proliferation/differentiation, migration and angiogenesis, most often by 
regulating the biological activities of cytokine/growth factors [44-46]. While the effects 
observed are independent of the autocrine SDF-1 (data not shown), IL-34 may also modulate 
angiogenesis by stimulating the secretion of VEGF, IP-10, MCP-1 or IL-8 (data not shown), 
data in agreement with those published by Eda et al. [17]. Recently, Nandi et al. identified the 
receptor-type protein-tyrosine phosphatase ζ (PTP-ζ) as a novel IL-34 receptor [47].  PTPζ is in 
fact predominantly expressed as a chondroitin sulfate proteoglycan and is highly abundant in 
the brain. In addition, PTP-ζ is expressed by endothelial cells and regulates endothelial cell 
migration by a strong interaction with ανβ3 [48].
 Overall, these data established a direct effect of 
IL-34 in endothelial cells through its binding to cell membrane-associated glycosaminoglycans. 
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This binding may explain in part the therapeutic benefit of glycosaminoglycans in the treatment 
against synovial inflammation in arthritis [49]. 
IL-34, like M-CSF, plays a part in the inflammatory process by the control of 
macrophage survival, migration and polarization [13, 14, 16, 18]. IL-34 drives in vitro the 
polarization of macrophages towards an immunosuppressive phenotype and function [15], data 
in agreement with our present in vivo observations. Numerous reports have described the 
accumulation of TAMs in tumour mass during their development. TAM density is associated 
with poor prognosis and release of trophic factors for tumour cells and angiogenesis.  
Consequently, TAMs facilitate the metastatic process [50]. In osteosarcoma, Buddingh et al. 
demonstrated that macrophages in osteosarcoma have both M1 and M2 characteristics. In 
addition, these authors observed an interesting relationship between CD14+/CD163+ M2 
macrophage and angiogenesis [51]. Our results are in agreement with these data and strengthen 
the involvement of IL-34 in the inflammation associated with cancer development. Indeed, IL-
34 promotes the adhesion of mononuclear phagocytes (monocyte/CD34+) to activated 
endothelial cells under physiological shear stress conditions. Il-34 may maintain the cancer 
inflammatory process by facilitating the extravasation of mononuclear phagocytes and may 
orientate the polarization of these cells toward an M2 phenotype. The phenomenon would be 
completed by the pro-angiogenic effect of IL-34 related to the M2 macrophage polarization 
and/or recruitment that increases the tumour vasculature as shown in vivo in the osteosarcoma 
model. Tumour growth and metastatic dissemination are significantly reduced in mice bearing 
an inactivation of the Macrophage-Colony Stimulating Factor (M-CSF) gene, due to 
angiogenesis impairment [52]. Similarly, DeNardo et al. provide evidence that the response to 
chemotherapeutic agents is partly controlled by the invaded mononuclear phagocytes [53]. In 
their work, chemotherapy induces mammary epithelial cells to produce pro-
monocyte/macrophage factors such as M-CSF and IL-34 that enhance TAM infiltration. 
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Interestingly, an antagonist inhibitor of the M-CSF receptor abolished M-CSF and IL-34 
activities and improved the survival of animal-bearing tumours (reduced initial tumour 
development and lung metastases). 
Although IL-34 has been characterized in the literature as the M-CSF “twin” cytokine 
showing common features, the present study revealed differential biological activities on the 
formation of vascular tubes (signaling pathways, functional interactions with FGF2, etc). Our 
results identify IL-34 as a novel cytokine promoting osteosarcoma progression by increasing 
the tissue vasculature, by stimulating the recruitment of macrophages and their differentiation 
toward M2 phenotype. Consequently, IL-34 appears as a pro-metastatic regulator in 
osteosarcoma. By regulating mononuclear phagocyte adhesion to the endothelium, 
angiogenesis and macrophage recruitment, our data suggest that IL-34 may play also a major 
role in inflammatory diseases. Targeting the M-CSF/IL-34/M-CSFR triad represents promising 
therapeutic approaches in oncology and autoimmune disorders. 
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FIGURE LEGENDS 
 
Figure 1: IL-34 promotes osteosarcoma growth, increases the number of lung metastases 
and the tumour vasculature in a mouse osteosarcoma model. Human HOS osteosarcoma 
cells overexpressing IL-34 (HOS-IL34), M-CSF (HOS-MCSF), transduced by the empty vector 
(HOS) were inoculated in close proximity to the tibia of female Rj:NMRI-nude mice (n=8 per 
group). (A) Follow-up of tumour volume for 27 days. (B) All mice were sacrificed by cervical 
dislocation at an equivalent volume of 1500 mm3 and the number of macroscopic lung 
metastases were scored manually. (C) immunohistochemical assessment of CD146 was carried 
out (Left Panel), and the percentage of CD146 positive vessel area was reported to the region of 
interest (R.O.I.) determined by ImageJ software (Right panel). *p < 0.05 compared to the 
control HOS group. 
 
 
Figure 2: IL-34 and M-CSF mediates the proliferation of endothelial colony-forming cells 
(ECFCs) and the tubule formation. (A-B) IL-34 and M-CSF induce ECFC proliferation in a 
dose-dependent manner after 48h of incubation. (C) IL-34 induces additive effect in the 
presence of FGF-2 after 24h of culture. (D-E) After 24h of culture in basal medium, in the 
presence or absence of 50 ng/mL IL34 and 100 ng/mL M-CSF, ECFCs were immediately 
seeded on Matrigel® in growth factor-depleted basal medium. After 18h of culture the cells 
were fixed and stained with Giemsa.. (D) Light-micrographs showing the typical appearance of 
tubules formed by control and pretreated ECFCs in Matrigel® (original magnification: x4).  (E) 
Comparison of the mean (± SEM) total length of tubules (% of control ECFCs) formed in 4 
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independent experiments. Results are normalized to untreated ECFCs. * p < 0.05, ** p < 0.01 
and *** p < 0.001, ### p < 0.001 compared to the  FGF2-stimulated ECFCs. 
 
Figure 3: The cell signalling induced by IL-34 in endothelial cells depends on cell surface 
glycosaminoglycans. Human ECFCs (A) and HUVECs (B-C) were treated with 200 ng/mL of 
IL-34 or M-CSF in the presence or absence of 5 ng/mL FGF-2 for 1 to 15 minutes (A, B) or for 
10 minutes (C). FAK, Akt, Src, ERK1/2 and p38 phoshorylations were analyzed by Western 
blot compared to the levels of GAPDH. (D) ECFCs were treated with 50 ng/mL of IL-34 in the 
presence or absence of 5 ng/mL FGF-2 and 10 µM of signalling pathway inhibitors (PF 
573228, a FAK inhibitor; PP2, a Src inhibitor; Wortmannin, a PI3K/Akt pathway inhibitor; 
UO126, an ERK1/2 inhibitor. ECFCs were then seeded on Matrigel® in growth factor-depleted 
basal medium. After 18h of culture the cells were fixed and stained with Giemsa. After 18h of 
culture, comparison of the mean (± SEM) total length of tubules (% of control ECFCs) formed 
in 3 independent experiments. Results are normalized to untreated ECFCs. (E) ECFCs were 
pretreated for 2 h at 37°C with a mixture of 0.5 U/mL heparinase I, II and III, and 0.2 U/ml 
chondroitinases A, B, and C, for 30 min before 50 ng/mL IL-34 stimulation. Light-micrographs 
show the typical appearance of tubules formed by IL-34 pretreated ECFCs in Matrigel®, 
markedly reduced after enzymatic treatment (original magnification: x4). (F) Similar enzymatic 
treatment as described above abolishes the IL-34-induced signalling pathways in HUVECs. * p 
< 0.05, ** p < 0.01 compared to the control condition (in absence of FGF2 and IL-34).  ## p < 
0.001 compared to the FGF2+ IL-34 condition). 
 
Figure 4: IL-34 increases the recruitment of TAM and their differentiation toward M2 
phenotype. Human HOS osteosarcoma cells overexpressing IL-34 (HOS-IL34), M-CSF (HOS-
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MCSF) or transduced by the empty vector (HOS pLv105) were inoculated in close proximity to 
the tibia of female Rj:NMRI-nude mice (n=8 per group). All mice were sacrificed by cervical 
dislocation at an equivalent volume of 1500 mm3 and immunohistochemical assessment of 
IBA-1 and Arginase-1 was carried out.  (A) Total IBA-1+ macrophages infiltrate into the tumor 
mass. (B) M2 Arginase-1+ macrophage infiltrate in the tumours. The percentage of IBA-1 and 
Arginase-1 positive staining area was reported to the region of interest (R.O.I.) determined by 
ImageJ software (B). *p < 0.05 compared to the control HOS group. 
 
Figure 5: IL-34 significantly increases the adherence of monocytes to activated-
endothelium under shear stress conditions. Before flow perfusion, freshly isolated 
mononuclear cells were incubated for 30 min in RPMI 1640, 10% FCS, supplemented or not 
with 50 ng/mL IL-34, labelled with calcein and then perfused over a confluent HUVEC 
monolayer previously activated at a shear rate of 50s-1 according to the procedure described in 
Zemani et al.22. (A, B) Adhesion of treated mononuclear cells to HUVEC monolayer. Arrow: 
calcein-labelled mononuclear cells adherent to the HUVEC monolayer. (C) Fractions of 
adherent and tethering cells in each experimental group. (D) Differential adherence between 
IL-34-treated monocytes and control cells at shear rates up to 2500 s-1. Values are mean ± SEM 
of seven determinations. * p < 0.05, **p < 0.01, ***p < 0.001 compared to the untreated 
control group. 
 
Figure 6: IL-34 significantly increases the adherence of CD34
+
 cells to activated-
endothelium. CD34+ cells were incubated as described in Figure 5 and the results were 
compared to those of monocytes.  IL-34 treatment of CD34+ cells resulted in a further 2-fold 
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increase in cell adhesion on activated HUVECs, similar to monocytes (A-B). The effects on 
CD34+ stem cell tethering were comparable to those observed with monocytes (C-D). 
However, the resistance to detachment of IL-34-treated CD34+ cells was lower than with 
monocytes in the same experimental conditions (E-F). * p < 0.05; **p < 0.01; ***p < 0.001 
compared to the control group. 
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